‘Surprised and Disappointed’ Santhera To Fight EU’s DMD Rejection

 
• By Neena Brizmohun and Maureen Kenny

Santhera has vowed to appeal against this week’s recommendation by the European Medicines Agency that the company’s application to extend Raxone’s indication to cover DMD be rejected. The agency recommended EU approval for four other drug applications seeking extended indications.

Businessman looking through a magnifying glass to documents
Santhera wants a re-examination of the EMA's decision on Raxone for Duchenne

More from Approvals

More from Product Reviews